NASDAQ:BGLC | Free Cash Flow | BioNexus Gene Lab Corp

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$147,671.00$325.00-$147,996.00
2025-12-31$961,062.00$977.00$960,085.00
2025-03-31-$824,072.00$9,052.00-$833,124.00
2024-12-31$219,203.00$4,022.00$215,181.00
2024-03-31-$37,153.00$21,945.00-$59,098.00
2023-12-31-$782,526.00$937.00-$783,463.00-253.99%
2023-03-31-$116,518.00$102.00-$116,620.00
2022-12-31$482,260.00-$37,144.00$445,116.00
2022-03-31-$37,839.00$32,191.00-$70,030.00-410.35%
2021-12-31$483,007.00$1,279.00$481,728.00539.79%
2021-03-31$115,428.00$807.00$114,621.0033.84%
2020-12-31$932,482.00$421,316.00$511,166.00
2020-03-31-$977,348.00$307.00-$977,655.00-91.40%
2019-12-31-$58,362.00$7,145.00-$65,507.00
2019-03-31-$48,561.00-$14,631.00-$63,192.00
2018-12-31$243,787.00-$17,292.00$226,495.00
2018-03-31-$673,561.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$1.84M$36,971.00-$1.88M
2024-12-31-$2.09M$226,989.00-$2.32M
2023-12-31-$1.82M$149,398.00-$1.97M
2022-12-31$551,822.00$0.00$551,822.00
2021-12-31$9,161.00$3,162.00$5,999.000.80%
2020-12-31$552,680.00$421,621.00$131,059.0011.98%
2019-12-31-$217,273.00$12,817.00-$230,090.00
2018-12-31-$274,080.00-$39,621.00-$313,701.00-1185.84%